Northwest Biotherapeutics INC

Northwest Biotherapeutics has entered into a $4.9 million convertible promissory note financing with Yorkville Advisors Global, LP, and a standby equity subscription agreement for up to $50 million.

Northwest Biotherapeutics, Inc. has completed the acquisition of Advent BioServices Ltd., a UK-based CDMO, for approximately $1.9 million plus outstanding payables.

Northwest Biotherapeutics, Inc. has reached a settlement in litigation concerning 2020 option awards, resulting in a $2.25 million payment to the company from insurers and the cancellation of 17% of challenged options.

Northwest Biotherapeutics stockholders approved an increase in authorized common stock, re-elected a director, and ratified executive compensation at their annual meeting.

Northwest Biotherapeutics, Inc. has secured a $5 million convertible promissory note to fund its UK manufacturing facility and operations.

Northwest Biotherapeutics, Inc. has secured a $5.5 million commercial loan from Streeterville Capital, LLC to fund ongoing business operations.

Northwest Biotherapeutics Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical trial efforts, significant operating losses, and substantial doubt regarding its ability to continue as a going concern.

Northwest Biotherapeutics reported increased net losses and a going concern warning for Q3 2025, while advancing its UK regulatory review and acquiring Advent BioServices.

Northwest Biotherapeutics reports reduced net losses and improved operating cash flow, while advancing its DCVax-L and DCVax-Direct cancer immunotherapy programs.

Northwest Biotherapeutics reports a net loss of $19.3 million for Q1 2025 while advancing its MAA application in the UK and developing its DCVax platform.

Northwest Biotherapeutics reported a net loss of $19.4 million for the third quarter of 2024, while continuing to advance its regulatory and clinical programs.

Northwest Biotherapeutics reported a net loss of $36.2 million for the first half of 2024, while advancing its regulatory application and pipeline development.

Northwest Biotherapeutics reports on its 2025 fiscal year, detailing operational progress, financial performance, and ongoing clinical development efforts for its DCVax therapies.

Northwest Biotherapeutics provides an update on its 2024 activities, including progress on its DCVax platform, regulatory submissions, and manufacturing developments.

Northwest Biotherapeutics has filed an amendment to its annual report to include previously omitted information regarding directors, executive officers, and corporate governance.

Northwest Biotherapeutics reports on its 2023 activities, including the submission of a Marketing Authorization Application for its DCVax-L product in the U.K. and advancements in its manufacturing capabilities.

Alton L. Boynton, Chief Scientific Officer of Northwest Biotherapeutics, reports gifting 1,000,000 stock options to family members for estate planning purposes.

Chief Technical Officer Marnix L. Bosch reports gifting 3,000,000 stock options to family members for estate planning purposes.

Alton L. Boynton, Chief Scientific Officer of Northwest Biotherapeutics, gifted 1,000,000 stock options to family members for estate planning purposes on August 8, 2024.

Director Navid Malik of Northwest Biotherapeutics sold 657,895 common stock options to former director Jerry Jasinowski on July 26, 2024.

Northwest Biotherapeutics, Inc. announces its 2025 Annual Meeting of Stockholders to vote on director election, auditor ratification, an increase in authorized common stock, and executive compensation.

Northwest Biotherapeutics provides instructions for stockholders to access the Annual Meeting on June 29, 2024, via an audio-only link or telephonically, emphasizing the need to vote proxies in advance.

Northwest Biotherapeutics is seeking stockholder approval for option awards granted to executives and directors in 2020, amidst a legal challenge questioning the fairness and process of these awards.